CMAB, an SIP-based comprehensive biomedicine business service supplier jointly founded by Suzhou Biomedicine Industrial Park (BioBay) and C-bridge Capital, came into operation on Mar 20.

The company comes out at a time when biomedicine has seen a fast development across the country and there is urgent need for transforming related research findings into productivity. It is expected to provide all-around services for biomedicine research, testing, mass production and domestic and overseas application for related permits, including tailored services based on clients' demands.

"We especially target multinationals and emerging businesses, trying to help them acquire higher quality services at lower cost and improve investment efficiency," the company's president Lian Qibin said.